Partnership to Help Accelerate Clinical Trials in Japan
Oct 23 2017 Read 234 Times
Parexel a global biopharmaceutical services provider and Osaka International Cancer Institute have formed an alliance to advance clinical development in Japan. The partnership will aim to drive greater efficiencies in support of patient recruitment for clinical trials in oncology and haematology, accelerating the development of innovative and effective new cancer treatments for patients.
“Oncology continues to be the largest therapeutic area in clinical trials today,and is a priority for Parexel as we partner with clients to deliver new therapies to patients in need,” said Shogo Nakamori, Corporate Vice President, Clinical Research Services, Asia Pacific, Parexel. “Osaka International Cancer Institute is a centre of excellence for clinical trials in the Kansai region of Japan. Through this alliance, Parexel and the Osaka International Cancer Institute will work to drive greater efficiencies for local and global biopharmaceutical companies, helping them accelerate the clinical development of innovative and effective new treatments in this difficult disease area.”
“The advancement of clinical trials in oncology is imperative in the development of promising new therapies for patients in Japan and around the world,” said Dr. Nariaki Matsuura, President of Osaka International Cancer Institute. “We are pleased to be working with Parexel, an innovative partner with a large presence in Japan,and globally, with leading clinical and scientific expertise in oncology. Through this collaboration, Osaka International Cancer Institute will gain access to novel treatments sooner, providing a wider range of potential treatment options for our patients and allowing us to make a strong contribution to the further advancement of cancer treatments.”
Do you like or dislike what you have read? Why not post a comment to tell others / the manufacturer and our Editor what you think. To leave comments please complete the form below. Providing the content is approved, your comment will be on screen in less than 24 hours. Leaving comments on product information and articles can assist with future editorial and article content. Post questions, thoughts or simply whether you like the content.
In This Edition Articles - Choosing the Optimum Plasma Spectrochemistry Technique for Measuring Elemental Impurities in Pharmaceuticals - Monitoring Airborne Molecular Contamination in Indoo...
View all digital editions
Jun 19 2018 Santiago de Compostela, Spain
Jun 20 2018 Cologne, Germany
Jun 27 2018 Tokyo, Japan
Jul 08 2018 Baltimore, MD, USA
Jul 29 2018 Chicago, IL, USA